Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

Rhea-AI Summary

Belite Bio (NASDAQ: BLTE) will deliver an oral presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) in Nanjing on May 22, 2026.

The talk will highlight previously disclosed Phase 3 DRAGON trial topline results for tinlarebant in adolescent Stargardt disease type 1, including a 35.7% reduction in atrophic retinal lesion growth versus placebo and a generally well tolerated safety profile.

News Market Reaction – BLTE

-4.63%

-4.63% Session close to close

In the May 15 session, BLTE declined 4.63%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement reiterates previously disclosed Phase 3 DRAGON topline results for tinlarebant, in...

Analysis

This announcement reiterates previously disclosed Phase 3 DRAGON topline results for tinlarebant, including a 35.7% reduction in atrophic retinal lesion growth versus placebo in Stargardt disease type 1 and generally well-tolerated safety. It mainly expands scientific and clinical visibility through an oral presentation at Retina China 2026. In recent months, Belite Bio has paired such presentations with regulatory progress, including a rolling NDA submission, making future regulatory updates and additional data key metrics to track.

Key Figures

Lesion growth reduction: 35.7% Phase: Phase 3 Conference edition: 27th +3 more

6 metrics

Lesion growth reduction 35.7% Reduction in growth rate of atrophic retinal lesions vs placebo in Phase 3 DRAGON

Phase Phase 3 DRAGON study of tinlarebant for Stargardt disease type 1

Conference edition 27th 27th Fundus Disease Forum and International Retinal Symposium

Conference dates May 21-23, 2026 Retina China 2026 in Nanjing, China

Presentation date May 22, 2026 Oral presentation slot for DRAGON topline results

Presentation time 1:54-2:02 p.m. CST Scheduled duration of Retina China 2026 talk

Historical Context

5 past events · Latest: Apr 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 27	Clinical data talk	Positive	+1.1%	Oral presentation of Phase 3 DRAGON topline results for tinlarebant.
Apr 23	Investor conferences	Neutral	-1.8%	Participation in four upcoming investor conferences to engage stakeholders.
Apr 21	Regulatory filing	Positive	+3.7%	Initiation of rolling NDA submission to FDA for tinlarebant in STGD1.
Mar 31	Annual report filed	Neutral	+6.9%	Form 20-F annual report filing and availability via company website.
Mar 02	Conference participation	Neutral	-6.7%	Participation in a fireside chat at the Leerink Global Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News tied to clinical and regulatory milestones, such as the NDA rolling submission, previously coincided with positive moves, while routine conference and filing updates have produced mixed reactions.

Recent Company History

Over the past few months, BLTE has highlighted several milestones around tinlarebant and corporate visibility. A March 31, 2026 Form 20-F availability notice followed a 6.88% move, while initiating a rolling NDA submission for Stargardt disease on April 21, 2026 preceded a 3.7% gain. Multiple conference participations and presentations, including Phase 3 DRAGON topline data, have shown both modest gains and pullbacks. Today’s Retina China 2026 presentation notice continues this pattern of expanding awareness for the same Phase 3 dataset.

Key Terms

phase 3, stargardt disease type 1, stgd1, atrophic retinal lesions, +1 more

5 terms

phase 3 medical

"Topline Results from the Phase 3 DRAGON Study of Tinlarebant..."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

stargardt disease type 1 medical

"tinlarebant for the treatment of Stargardt disease type 1 (STGD1)."

An inherited genetic eye disorder that gradually damages the central part of the retina responsible for sharp, detailed vision, often starting in childhood or early adulthood; think of a camera slowly losing the pixels that capture fine detail. It matters to investors because the condition creates a focused market for diagnostics, treatments and gene or cell therapies, so progress in research, regulatory approvals, or trial results can materially affect companies developing and commercializing those solutions.

stgd1 medical

"tinlarebant for the treatment of Stargardt disease type 1 (STGD1)."

STGD1 is a hereditary eye disease caused by mutations that progressively damage the light-sensing cells in the central retina, leading to loss of sharp, detailed vision. For investors, it matters because it defines a clear patient population and medical need—like a camera slowly losing its central pixels—making it a common target for drug and gene therapies, clinical trials, regulatory decisions, and potential market opportunities in ophthalmology.

atrophic retinal lesions medical

"reduction in the growth rate of atrophic retinal lesions compared to placebo"

Atrophic retinal lesions are patches where the light-sensitive layer at the back of the eye has thinned or broken down, often causing permanent loss of vision in the affected areas. For investors, they matter because the presence, progression, or improvement of these lesions drives demand for treatments, influences clinical trial outcomes and regulatory decisions, and therefore affects the market potential and valuation of companies working on therapies or diagnostics.

placebo medical

"reduction in the growth rate of atrophic retinal lesions compared to placebo"

A placebo is an inactive pill, injection or procedure that looks and feels like the real treatment but contains no therapeutic ingredient, often called a sugar pill. Investors care because comparing a drug to a placebo reveals whether observed benefits come from the medicine itself or from expectation; clear superiority over placebo reduces regulatory and commercial risk, much like a blind taste test proves a new recipe really tastes better.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will give an oral presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) being held from May 21-23, 2026, in Nanjing, China.

The presentation will cover the previously disclosed positive topline results from the Phase 3 DRAGON trial, which evaluated tinlarebant for the treatment of Stargardt disease type 1 (STGD1). In the study, tinlarebant demonstrated a clinically meaningful 35.7% reduction in the growth rate of atrophic retinal lesions compared to placebo and was generally well tolerated with side effects consistent with its mechanism of action.

Presentation Details
Session: Fundus Disease in Children
Title: Topline Results from the Phase 3 DRAGON Study of Tinlarebant for Adolescent Stargardt’s Disease
Presenter: Ruifang Sui, M.D., Ph.D., Peking Union Medical College Hospital
Date and Time: May 22, 2026, 1:54-2:02 p.m. CST
Location: Nanjing Yangtze River International Conference Center, No. 299, Jiangbin Avenue, Pukou District, Nanjing, Jiangsu Province, China

About Tinlarebant (a/k/a LBS-008)
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1 and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., Orphan Drug Designation in the U.S., Europe, Japan, and Sakigake Designation in Japan for the treatment of STGD1. In April 2026, Belite Bio initiated a rolling submission to the U.S. Food and Drug Administration for tinlarebant in the treatment of STGD1.

About Stargardt Disease (STGD1)
STGD1 is the most common inherited macular dystrophy in both adults and children. The disease is caused by mutations in a retina-specific gene (ABCA4), which results in progressive accumulation of bisretinoids leading to retinal cell death and progressive loss of central vision. The fluorescent properties of bisretinoids and the development of high-resolution retinal imaging systems have helped ophthalmologists identify and monitor disease progression. Currently, there are no approved treatments for STGD1.

About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

FAQ

What will Belite Bio (NASDAQ: BLTE) present at Retina China 2026?

Belite Bio will present previously disclosed topline results from the Phase 3 DRAGON trial of tinlarebant in adolescent Stargardt disease type 1. According to Belite Bio, the study showed a 35.7% reduction in atrophic retinal lesion growth versus placebo and generally well tolerated safety.

When and where is Belite Bio presenting its DRAGON Phase 3 data at Retina China 2026?

Belite Bio’s oral presentation is scheduled for May 22, 2026, from 1:54 to 2:02 p.m. CST. According to Belite Bio, it will take place at Nanjing Yangtze River International Conference Center in Nanjing, Jiangsu Province, China.

What were the key Phase 3 DRAGON trial results for tinlarebant in Stargardt disease?

Tinlarebant achieved a 35.7% reduction in the growth rate of atrophic retinal lesions versus placebo in the Phase 3 DRAGON trial. According to Belite Bio, tinlarebant was generally well tolerated with side effects consistent with its mechanism of action.

Who will present Belite Bio’s DRAGON trial results at Retina China 2026?

The DRAGON trial results will be presented by Ruifang Sui, M.D., Ph.D., from Peking Union Medical College Hospital. According to Belite Bio, the session is part of the Fundus Disease in Children track at Retina China 2026.

What condition does tinlarebant target in Belite Bio’s Phase 3 DRAGON study?

Tinlarebant targets Stargardt disease type 1 (STGD1) in adolescents in the Phase 3 DRAGON trial. According to Belite Bio, the trial evaluated tinlarebant’s effect on atrophic retinal lesion growth and its overall tolerability compared with placebo.